226 related articles for article (PubMed ID: 30694571)
1. Relapse pattern and long-term outcomes in subjects with acquired haemophilia A.
Mizrahi T; Doyon K; Dubé E; Bonnefoy A; Warner M; Cloutier S; Demers C; Castilloux JF; Rivard GE; St-Louis J
Haemophilia; 2019 Mar; 25(2):252-257. PubMed ID: 30694571
[TBL] [Abstract][Full Text] [Related]
2. The factor VIII:C/VWF:Ag ratio as a useful tool to predict relapse in patients with acquired haemophilia A: A retrospective cohort study.
Trossaert M; Graveleau J; Thiercelin-Legrand MF; Sigaud M; Guerrero F; Neel A; Fouassier M; Sailler L; Chauveau D; Ternisien C; Huart A; Gillet B; Hamidou M; Bene MC; Voisin S
Haemophilia; 2019 May; 25(3):527-534. PubMed ID: 31050100
[TBL] [Abstract][Full Text] [Related]
3. Identifying risk factors and optimizing standard of care for patients with acquired haemophilia A: Results from a Czech patient cohort.
Salaj P; Geierová V; Ivanová E; Loužil J; Pohlreichová V; Hrachovinová I; Dulíček P
Haemophilia; 2020 Jul; 26(4):643-651. PubMed ID: 32590889
[TBL] [Abstract][Full Text] [Related]
4. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy.
Field JJ; Fenske TS; Blinder MA
Haemophilia; 2007 Jan; 13(1):46-50. PubMed ID: 17212724
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors in haemophilia A: current management and open issues.
Haya S; Moret A; Cid AR; Cortina V; Casaña P; Cabrera N; Aznar JA
Haemophilia; 2007 Dec; 13 Suppl 5():52-60. PubMed ID: 18078398
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study.
Tiede A; Klamroth R; Scharf RE; Trappe RU; Holstein K; Huth-Kühne A; Gottstein S; Geisen U; Schenk J; Scholz U; Schilling K; Neumeister P; Miesbach W; Manner D; Greil R; von Auer C; Krause M; Leimkühler K; Kalus U; Blumtritt JM; Werwitzke S; Budde E; Koch A; Knöbl P
Blood; 2015 Feb; 125(7):1091-7. PubMed ID: 25525118
[TBL] [Abstract][Full Text] [Related]
7. Overshoot of FVIII activity in patients with acquired hemophilia A who achieve complete remission.
Ogawa Y; Yanagisawa K; Naito C; Uchiumi H; Ishizaki T; Shimizu H; Gohda F; Ieko M; Ichinose A; Handa H
Int J Hematol; 2020 Apr; 111(4):544-549. PubMed ID: 31939075
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A.
Batty P; Moore GW; Platton S; Maloney JC; Palmer B; Bowles L; Pasi KJ; Rangarajan S; Hart DP
Thromb Haemost; 2015 Oct; 114(4):804-11. PubMed ID: 26063073
[TBL] [Abstract][Full Text] [Related]
9. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry.
Tengborn L; Baudo F; Huth-Kühne A; Knoebl P; Lévesque H; Marco P; Pellegrini F; Nemes L; Collins P;
BJOG; 2012 Nov; 119(12):1529-37. PubMed ID: 22901076
[TBL] [Abstract][Full Text] [Related]
10. Acquired haemophilia syndrome: pathophysiology and therapy.
Elezović I
Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():64-8. PubMed ID: 20229686
[TBL] [Abstract][Full Text] [Related]
11. Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational study.
Dobbelstein C; Moschovakis GL; Tiede A
Ann Hematol; 2020 Sep; 99(9):2105-2112. PubMed ID: 32621181
[TBL] [Abstract][Full Text] [Related]
12. Outcome of CARE: a 6-year national registry of acquired haemophilia A in China.
Sun B; Xue F; Feng Y; Sun J; Yu Z; Hou M; Zhang J; Zeng X; Zhao Y; Lian S; Huang M; Niu T; Cui Z; Wu J; Yang R
Br J Haematol; 2019 Dec; 187(5):653-665. PubMed ID: 31372978
[TBL] [Abstract][Full Text] [Related]
13. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies.
Holme PA; Brosstad F; Tjønnfjord GE
Haemophilia; 2005 Sep; 11(5):510-5. PubMed ID: 16128896
[TBL] [Abstract][Full Text] [Related]
14. New protocol for immune tolerance induction in acquired hemophilia.
Nemes L; Pitlik E
Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
[TBL] [Abstract][Full Text] [Related]
15. A low-dose rituximab regimen for first-line treatment of acquired haemophilia A.
Hunt S; Robertson J; Conn J; Casey J; Royle J; Collins J; Hourigan M; Richmond J; Yang Wang T; Mills A; Mason J
Eur J Haematol; 2022 Jan; 108(1):28-33. PubMed ID: 34528303
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of sample preheat treatment in a modified Nijmegen-Bethesda assay (mNBA) for inhibitor monitoring in congenital and acquired haemophilia A: A single-centre four-year experience.
Gandhi T; Lawler P; Foxton E; Chowdary P; Riddell A
Haemophilia; 2020 Nov; 26(6):e300-e307. PubMed ID: 32892451
[TBL] [Abstract][Full Text] [Related]
17. Cross-reacting recombinant porcine FVIII inhibitors in patients with acquired haemophilia A.
Bowyer A; Shepherd F; Platton S; Guy S; Kitchen S; Maclean R
Haemophilia; 2020 Nov; 26(6):1181-1186. PubMed ID: 32997894
[TBL] [Abstract][Full Text] [Related]
18. Treatment of minor severe acquired haemophilia. Is there a rationale for immunoadsorption?
Goldmann G; Marquardt N; Horneff S; Oldenburg J; Zeitler H
Atheroscler Suppl; 2015 May; 18():74-9. PubMed ID: 25936308
[TBL] [Abstract][Full Text] [Related]
19. Emicizumab for the treatment of acquired hemophilia A.
Knoebl P; Thaler J; Jilma P; Quehenberger P; Gleixner K; Sperr WR
Blood; 2021 Jan; 137(3):410-419. PubMed ID: 32766881
[TBL] [Abstract][Full Text] [Related]
20. Postoperative paraneoplastic factor VIII auto-antibodies in patients with solid tumours.
Reitter S; Knoebl P; Pabinger I; Lechner K
Haemophilia; 2011 Sep; 17(5):e889-94. PubMed ID: 21457407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
